Research Article
Correlation between PPAR Gene Polymorphisms and Primary Nephrotic Syndrome in Children

Jiaping Jin, Guixia Ding, Huaying Bao, Ying Chen, Yuan Han, Fei Zhao, Songming Huang, and Aihua Zhang

1 Department of Nephrology, Nanjing Children’s Hospital, Nanjing Medical University, 72 Guangzhou Road, Nanjing, Jiangsu 210008, China
2 Institute of Pediatrics, Nanjing Medical University, Nanjing, Jiangsu 210029, China

Correspondence should be addressed to Aihua Zhang; zhaihua@njmu.edu.cn

Received 1 July 2013; Accepted 11 August 2013

Academic Editor: Zhanjun Jia

Copyright © 2013 Jiaping Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pediatric primary nephrotic syndrome (PNS) is a chronic disease promoted by metabolic and immune dysfunctions. Peroxisome proliferator-activated receptor (PPAR) polymorphisms have been associated with a variety of metabolic and kidney disorders. We therefore hypothesized that PPAR polymorphisms might be involved in the pathophysiology of PNS. We compared the distributions of the PPAR-γ Pro12Ala and Val290Met, PPAR-γ coactivator-α (PGC-1α) Gly482Ser, and PPAR-α Leu162Val single nucleotide polymorphisms (SNPs) between children with PNS and normal controls and analyzed their correlations with clinical and metabolic indicators and steroid responsiveness. There were no significant differences in distributions of any of the polymorphisms between PNS cases and controls. However, PNS patients with the PPAR-γ (Pro12Ala) PP genotype had significantly higher fasting serum insulin, IgA, and HOMA-IR levels and lower insulin sensitivity than did patients with PA and AA genotypes. Additionally, the PGC-1α (Gly482Ser) A allele was associated with lower CD8+ T-cell counts and higher triglyceride and complement C3 levels compared with the G allele. No polymorphisms were related to hormone sensitivity. These results suggest that the PPAR-γ (Pro12Ala) and PGC-1α (Gly482Ser) SNPs may influence insulin and triglyceride metabolism in children with PNS and may thus be relevant to the prognosis of this chronic condition.

1. Introduction

Peroxisome proliferator-activated receptors (PPARs) are a group of ligand-activated nuclear transcription factors belonging to the type II nuclear receptor superfamily. Three PPAR subtypes, PPAR-α, PPAR-β, and PPAR-γ, have been identified in amphibians, rodents, and humans [1]. Recent studies have shown associations between PPAR gene polymorphisms and metabolic syndrome (MS) and the development of insulin resistance (IR). Gouda et al. [2] performed a meta-analysis of 32,849 patients with type II diabetes mellitus (T2DM) and 47,456 normal controls and found that the PPAR-γ (Pro12Ala) gene polymorphism was associated with IR and T2DM. In addition, Sparso et al. [3] showed that the PPAR-α (Leu162Val) gene polymorphism was associated with obesity, T2DM, and abnormal lipid metabolism, while Andruhonyte et al. [4] found a link between the PPAR-γ coactivator-α (PGC-1α) Gly482Ser gene polymorphism and conversion from impaired glucose tolerance to T2DM.

Children with primary nephrotic syndrome (PNS) suffer from metabolic abnormalities including glycolipid disorders, altered hemodynamics, and immune dysfunction, and previous studies have demonstrated that these disorders promote the progression of renal diseases and the development of end-stage renal disease (ESRD) [5]. Furthermore, the Ala allele of PPAR-γ was shown to be associated with a reduced glomerular filtration rate (GFR) and increased occurrences of ESRD, cardiovascular events, and mortality in patients with diabetic nephropathy [6]. We therefore hypothesized that PPAR gene polymorphisms may be associated with
the occurrence, clinical manifestations, pathological type, and treatment response in patients with PNS. A better understanding of these relationships may provide a theoretical basis for further studies of the pathophysiological role of PPARs in PNS.

We tested this hypothesis using clinical data from children with PNS and from healthy children (normal controls, NCs). The distributions of the single nucleotide polymorphisms (SNPs) Pro12Ala and Val290Met in the PPAR-γ gene, Gly482Ser in the PGC-1α gene, and Leu162Val in the PPAR-α gene were determined in PNS and NC children. In addition, the associations between these polymorphisms and clinical metabolic indicators, proteinuria, renal pathology, and treatment response in patients with PNS were examined to investigate the pathophysiological role of PPARs in PNS and to determine the potential role of these polymorphisms in treatment planning and prognosis determination in children with PNS.

2. Subjects and Methods

2.1. Subjects. Patients with a diagnosis of PNS treated at the Nanjing Children's Hospital, China, between July 2008 and November 2010 were evaluated. Genotype determinations for Pro12Ala and Val290Met of the PPAR-γ gene and Leu162Val of the PPAR-α gene were performed in 111 PNS patients (80 male, 31 female; mean age 3.33 years, range 0.67–13.08). Genotype determination for Gly482Ser of the PGC-1α gene was performed in 108 patients (78 male, 30 female; mean age 3.47 years, 0.67–13.08). All subjects were diagnosed with PNS according to the diagnostic criteria outlined by the clinical classification diagnosis and treatment of glomerular disease in children [7]. The presence of secondary kidney disease was excluded. None of the included patients were receiving β-blockers, diuretics, calcium-channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, glucocorticoids, or other immunosuppressants at the time of inclusion.

All patients were followed for between 4 months and 2.5 years, and the duration of followup reflected the response to glucocorticoids. Patients who received steroids were divided into three groups: steroid-responsive nephrotic syndrome (NS), where urine was negative for protein within 8 weeks of treatment (𝑛= 83), steroid-resistant NS, where urine still contained protein at 8 weeks (𝑛= 13), and steroid-dependent NS, where urinary protein reappeared after the steroid dose was reduced (𝑛= 12).

NCs were recruited from patients admitted to the hospital for elective surgery. Genotype determinations for Pro12Ala and Val290Met of the PPAR-γ gene and Leu162Val of the PPAR-α gene were performed in 111 healthy children who received a physical examination at our hospital (94 male, 17 female; mean age 3.5 years, range 0.80–10.75). Genotype determination for Gly482Ser of the PGC-1α gene was performed in 110 NCs (93 male, 17 female; mean age 3.5 years, range 0.80–10.75). A detailed check of medical history was performed to exclude children who had been premature and of low birth weight, had macrosomia, or whose mother had gestational diabetes mellitus or any other significant conditions. Age, sex, and body mass index (BMI) did not differ significantly between the NC and PNS children.

The local ethics committee approved the study, and informed consent was obtained from all participating children and their parents.

2.2. Detection of SNP Positions and Sequencing of PCR Products. DNA was extracted from peripheral venous blood using a genomic DNA purification kit (Qiagen Sciences, Germantown, MD, USA). The SNP genotypes were examined using polymerase chain reaction (PCR) restriction fragment length polymorphism. The primers were synthesized by Invitrogen, and the sequences were as follows: PPAR-γ Pro12Ala sense, 5'-CAAGCCCAGTCTTTTCTGTG-3'; antisense, 5'-GCTTTCGCTAAAGGAATGTA-3'; PPAR-γ Val290Met sense, 5'-ATTCTTTAATGTGGGAGA-3'; antisense, 5'-TCTCTTAGTGTCCTACGTT-3'; PPAR-α Leu162Val sense, 5'-GACTCAAAGCTGGTATGACAGT-3'; antisense, 5'-TAAGACAGCTCTACGTTGTC-3'; and PGC-1α Gly482Ser sense, 5'-TGCTACCTGAGGAGACTTTG-3'; antisense, 5'-CTTTCATCTTTCGCTGTCATC-3'.

2.3. Physical Measurements. Height and weight were measured in all participants, and the mean of three measurements was used to calculate BMI (BMI = weight/height² (kg/m²)). Blood pressure (BP) was measured using the brachial artery of the right arm (either in a seated position or in the mother's arms), and the process was repeated 2 min later. The mean value of both readings was recorded as the BP for each individual.

2.4. Blood Tests. Blood samples were taken from all participants following a bland meal the previous evening and an overnight fast. Fasting blood glucose (FBG), fasting serum insulin (FISN), fasting serum C-peptide (FCP), blood lipids,
renal function, and coagulation were measured. All samples were obtained prior to steroid treatment. The kits for serum measurements and the 7600 automatic biochemical analyzer were provided by Hitachi (Japan). FISN and FCP were tested by chemiluminescence assays using kits and an Elecsys 2010 (Roche).

### 2.5. Calculation of HOMA-IR, Islet β-Cell Function, and Insulin Sensitivity Index

Homeostasis model assessment of insulin resistance (HOMA-IR), islet β-cell function (HOMA-islet), and insulin sensitivity index (ISI) were calculated using the following formulae: HOMA-IR = FBG × FISN/22.5; HOMA-islet = 20 × FISN/(FBG − 3.5); ISI = ln(1/FBG × FISN) \( [7] \) (FISN mU/L; FBG mmol/L).

### 2.6. Statistical Analyses

The group representation of the distribution of sample genotypes was estimated using the Hardy-Weinberg equilibrium. The frequency of each genotype was calculated using the gene-counting method. Normally distributed data were presented as mean ± standard deviation, and nonnormally distributed data were presented as median (range). The means of two groups with normal distributions were compared using t-tests or analysis of variance, and nonnormally distributed data were compared using non-parametric tests. Classified data were analyzed using χ² tests or logistic regression. Analyses were performed using SPSS 16.0 software, and \( P \) values < 0.05 were considered statistically significant.

### 3. Results

#### 3.1. Comparison of PPAR-γ (Pro12Ala) and PGC-1α (Gly482Ser) Genotypes between PNS and NC Groups

The frequencies of the PPAR-γ (Pro12Ala) and PGC-1α (Gly482Ser) genotypes in NC children conformed to the Hardy-Weinberg equilibrium. There were no significant differences in distributions of the PPAR-γ (Pro12Ala) and PGC-1α (Gly482Ser) genotypes between PNS and NC children (\( P > 0.99 \) and \( P = 0.324 \), resp.). The results are shown in Tables 1 and 2.

#### 3.2. Comparison of Clinical Data between Individuals with Different Genotypes in the PNS Group

The results of a further-stratified analysis of the PPAR-γ (Pro12Ala) genotypes in PNS children are shown in Table 3. There were no significant differences in any of the following parameters among children with PNS with different PPAR-γ (Pro12Ala) genotypes: sex, age, BMI, levels of albumin (ALB), blood urea nitrogen (BUN), serum creatinine (Scr), blood uric acid (UA), GFR, total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDLC), fibrinogen (Fbg), FBG, FCP, immunoglobulin G/M (IgG and IgM), complement C3 and C4, frequencies of CD3+ T cells, CD4+ T cells, CD8+ T cells, NK cells, and B lymphocytes, HOMA-islet values, and 24h urine protein (24-UP). However, patients with the PP genotype demonstrated significantly higher levels of FISN,
Table 1: The distribution of PPAR-\(\gamma\) (Pro12Ala) genotypes among PNS and NC children.

| PPAR-\(\gamma\) genotype | PNS group | NC group | \(\chi^2\) | OR (95% CI) | \(P\) value |
|--------------------------|-----------|----------|------------|-------------|-------------|
| PP                       | 103       | 103      | 1.031      | 1           | 1.000       |
| PA/AA                    | 8         | 8        | 1.000 (0.312–2.766) | 1            |

Table 2: The distribution of PGC-1\(\alpha\) (Gly482Ser) genotypes among PNS and NC children.

| PGC-1\(\alpha\) genotype | PNS group | NC group | \(\chi^2\) | OR (95% CI) | \(P\) value |
|--------------------------|-----------|----------|------------|-------------|-------------|
| GG                       | 18        | 20       | 2.253      | 1.037 (0.502–2.144) | 0.324       |
| GA                       | 59        | 68       | 0.639      | 0.276–1.478 | 0.324       |
| AA                       | 31        | 22       | 1          | 1           | 1           |

Table 3: Stratified analysis of the PPAR-\(\gamma\) (Pro12Ala) genotypes among PNS children.

| Subjects                  | PP         | PA/AA     | \(t/t'\chi^2/z\) | \(P\) value |
|---------------------------|------------|-----------|------------------|-------------|
| Gender (male/female)      | 74/29      | 6/2       | 0.000            | 1.000       |
| Age (years)               | 3.67 (0.67–13.08) | 3.00 (1.50–4.25) | −1.562    | 0.118       |
| BMI                       | 17.07 ± 0.22 | 17.24 ± 0.77 | −0.205    | 0.858       |
| sBP (kp)                  | 14.28 ± 0.14 | 14.21 ± 0.29 | 0.120     | 0.905       |
| BMI                       | 9.16 ± 0.10  | 9.18 ± 0.37 | −0.046    | 0.963       |
| ALB (g/L)                 | 17.70 (11.20–37.00) | 18.95 (16.80–26.30) | −1.283 | 0.199       |
| BUN (mmol/L)              | 4.00 (0.50–16.30) | 2.60 (2.20–21.50) | −1.689 | 0.091       |
| Scr (\(\mu\)mol/L)       | 37.20 (18.30–207.60) | 33.45 (27.60–51.50) | −1.032 | 0.302       |
| UA (mmol/L)               | 350.76 ± 10.96 | 347.88 ± 34.60 | 0.071     | 0.943       |
| GFR (mL/(min·1.73 m\(^2\))) | 137.54 ± 3.47 | 137.56 ± 8.75 | −0.002 | 0.999       |
| TC (mmol/L)               | 9.89 ± 0.28  | 9.37 ± 0.76  | 0.498     | 0.619       |
| TG (mmol/L)               | 2.46 (0.77–8.03) | 2.26 (1.36–6.33) | −0.160   | 0.873       |
| HDL-c (mmol/L)            | 1.49 ± 0.06  | 1.46 ± 0.18  | 0.170     | 0.865       |
| Fbg (g/L)                 | 4.58 ± 0.16  | 3.37 ± 2.26  | 0.536     | 0.686       |
| IgA (g/L)                 | 1.06 ± 0.04  | 0.81 ± 0.08  | 2.701     | 0.020       |
| IgG (g/L)                 | 2.26 (1.36–11.00) | 2.31 (1.46–4.79) | −0.364  | 0.716       |
| IgM (g/L)                 | 1.70 ± 0.06  | 1.92 ± 0.27  | −0.934    | 0.352       |
| C3 (g/L)                  | 2.49 ± 1.22  | 1.28 ± 0.06  | 0.279     | 0.781       |
| C4 (g/L)                  | 0.29 ± 0.01  | 0.27 ± 0.02  | 0.484     | 0.629       |
| T (CD3+) (%)              | 68.95 ± 1.09 | 60.00 ± 7.11 | 1.700     | 0.093       |
| T (CD4+) (%)              | 35.62 ± 0.96 | 31.25 ± 6.42 | 0.940     | 0.350       |
| T (CD8+) (%)              | 27.92 ± 0.76 | 21.50 ± 3.95 | 1.764     | 0.081       |
| NK (%)                    | 8.00 (2.00–44.00) | 5.00 (2.00–31.00) | −0.943 | 0.367       |
| BC (%)                    | 18.85 ± 0.87 | 23.75 ± 6.18 | −1.156   | 0.251       |
| FBG (mmol/L)              | 4.88 ± 0.06  | 4.84 ± 0.26  | 0.162     | 0.872       |
| FISN (mU/L)               | 2.27 (0.20–16.63) | 0.92 (0.20–3.17) | −2.526   | 0.012       |
| FCP (nmol/L)              | 0.47 (0.18–1.95) | 0.41 (0.22–0.98) | −0.981   | 0.327       |
| HOMA-IR                   | 0.48 (0.04–4.31) | 0.16 (0.05–0.82) | −2.566   | 0.060       |
| HOMA-islet                | 38.06 (−141.54–895.56) | 27.06 (2.50–90.94) | −1.460   | 0.144       |
| ISI                       | −2.46 ± 0.10 | −1.46 ± 0.33 | −2.777   | 0.006       |
| 24-h UP (mg/kg)           | 141.15 (2.96–1179.80) | 117.84 (7.41–410.00) | −0.871   | 0.384       |

\(^*P < 0.05, **P < 0.01.\)
IgA, and HOMA-IR and lower levels of ISI compared with patients with PA and AA genotypes.

The results of a further-stratified analysis of the PGC-\(\alpha\) (Gly482Ser) genotypes among PNS children are shown in Table 4. There were no significant differences in any of the following parameters among children with PNS with different PGC-\(\alpha\) (Gly482Ser) genotypes: sex, age, BMI, ALB, BUN, Scr, UA, GFR, TC, HDL-c, Fbg, IgA, IgG, IgM, FBG, FISN, FCP, and C4, frequencies of CD3+ T cells, CD4+ T cells, NK cells, and B lymphocytes, HOMA-IR, HOMA-islet, ISI values, and 24-UP. However, patients with the A allele demonstrated lower levels of CD4+ T cells and higher levels of TG and complement C3 than did patients with the G allele.

The distribution of genes among children with PNS of different pathological types was analyzed by single-factor analysis of variance. There were no significant differences in PPAR-\(\gamma\) (Pro12Ala) and PGC-\(\alpha\) (Gly482Ser) genotypes between individuals with different renal pathological types. The results are shown in Tables 5 and 6.

Gene distributions among children with PNS who demonstrated different responses to hormone treatment were analyzed by \(\chi^2\) tests and single-factor analysis of variance. There were no significant differences in PPAR-\(\gamma\) (Pro12Ala) and PGC-\(\alpha\) (Gly482Ser) genotypes among patients with different responses to hormone treatment. The results are shown in Tables 7 and 8.

4. Discussion

PPAR-\(\gamma\) receptors can be divided into three subtypes: \(\gamma1\), \(\gamma2\), and \(\gamma3\). Several PPAR-\(\gamma2\) mutations have been discovered, of which the most common is the CCA-GCA mutation at the 12th codon in exon 2, which results in the conversion of proline to alanine. This Pro12Ala gene polymorphism was first reported by Chung-Jen et al. [8] in a study of 34 Caucasian individuals. The mutation frequencies for Pro12Ala vary greatly among different ethnic groups: 12% in Caucasians, 10% in Americans, 4% in Japanese, and 2% in Chinese. Our study found the frequency of the A allele to be 3.8% and that of the P allele to be 96.2%. Other gene mutations of PPAR-\(\gamma2\) (Pro12Ala, Val290Met, and Rro467Leu) exist at low frequencies and have smaller impacts on the population; however, the manifestations of these mutations include severe IR, local abnormal lipid metabolism, T2DM, and hypertension. The current study demonstrated that the Pro12Ala mutation and blood lipid levels, cardiovascular events, insulin sensitivity, T2DM, and renal function [2, 6, 9, 10]. Compared with NC children, children with PNS demonstrated increased BP, decreased GFR, increased Scr, hyperuricemia, hyperlipidemia, increased serum C-peptide levels, and decreased islet \(\beta\)-cell function during the early stage of the disease, though these patients did not demonstrate IR, a hypercoagulable state, or evidence of an immune inflammatory response. These results suggest that these characteristics may be correlated with the Pro12Ala gene polymorphism. We analyzed the distributions of two different genotypes in PNS and NC children and unexpectedly found no association between the Pro12Ala gene polymorphism and PNS occurrence. A further-stratified analysis in children with PNS showed that insulin levels and islet \(\beta\)-cell function were decreased and insulin sensitivity was increased in patients with the A allele, after matching for age, sex, and BMI. Stefan et al. [11] demonstrated that this mutation was associated with free fatty acid-induced reduction of second-phase insulin secretion in a healthy population with normal body weight. Furthermore, a large population study in Italian and Brazilian Caucasians showed that the A allele was significantly associated with increased insulin sensitivity [12], suggesting that the A allele may have distinct effects on insulin secretion and insulin sensitivity. However, the effects of the Pro12Ala polymorphism on insulin secretion and sensitivity remain inconclusive. Although most studies have shown that patients with mutations at this site have decreased insulin secretion capacity and increased insulin sensitivity, the specific mechanisms responsible for these effects remain unclear.

Previous studies confirmed that PPAR-\(\gamma\) participates in the pathophysiology of kidney diseases; its activation can reduce BP, delay renal arteriosclerosis, reduce proteinuria and Scr, and reverse the process of glomerulosclerosis and interstitial fibrosis, which are closely associated with prognosis in patients with kidney diseases. The Cys161Thr polymorphism of the PPAR-\(\gamma2\) gene is associated with survival in patients with nonhypertensive IgA nephropathy [13]. We analyzed the association between the Pro12Ala polymorphism of the PPAR-\(\gamma2\) gene and response to treatment in PNS patients and found no differences in genotype distributions between hormone-sensitive, hormone-resistant, and hormone-dependent patients. We were therefore unable to conclude that the Pro12Ala polymorphism of PPAR-\(\gamma2\) could predict response to hormone treatment. Although no mutations in this gene were detected in children in the hormone-resistant group, this could have been because of the low mutation frequency of the A allele or the small sample size. In addition, the follow-up period in this study was short, and indicators such as progression to ESRD, survival rate, and complications could not be compared. Further follow-up studies are needed to address these factors.

Evidence has shown that PGC-\(\alpha\) is closely associated with MS and IR, and studies in different ethnic groups have found linkage between the chromosomal fragment of the PGC-\(\alpha\) gene and MS-related manifestations. Our study demonstrated that the frequency of the G allele was 46.6% and that of the A allele was 53.4%. Many previous studies have shown associations between the Gly482Ser polymorphism of the PGC-\(\alpha\) gene and IR, obesity, and type II diabetes [4]. Compared with NC children, children with PNS demonstrated increased BP, decreased GFR, increased Scr, hyperuricemia, hyperlipidemia, increased FCP, and decreased islet \(\beta\)-cell function at the time of disease onset, but did not have apparent IR, a hypercoagulable state, or evidence of an immune inflammatory response. We therefore speculated that this phenomenon might be associated with
Table 4: Stratified analysis of the PGC-1α (Gly482Ser) genotypes among PNS children.

| Subjects                  | PGC-1α gene | GA   | AA   | GG   | $\chi^2/F$ | P value |
|---------------------------|-------------|------|------|------|------------|---------|
| Gender (male/female)      |             | 46/13| 21/10| 11/7 |            |         |
| Age (years)               |             | 3.60 (1.50–13.08) | 3.00 (0.67–10.58) | 4.40 (1.33–9.80) | 2.388 | 0.303   |
| BMI                       |             | 16.84 ± 0.29 | 17.47 ± 0.36 | 16.98 ± 0.54 | 0.874 | 0.420   |
| sBP (kp)                  |             | 14.18 ± 0.17 | 14.36 ± 0.29 | 14.49 ± 0.34 | 0.384 | 0.682   |
| dBP (kp)                  |             | 9.15 ± 0.13 | 9.14 ± 0.18 | 9.19 ± 0.32 | 0.014 | 0.986   |
| ALB (g/L)                 |             | 17.60 (11.20–37.00) | 18.10 (12.80–26.30) | 18.40 (11.30–27.60) | 0.327 | 0.849   |
| BUN (mmol/L)              |             | 4.10 (2.30–21.50) | 3.50 (0.50–16.30) | 3.85 (2.20–13.10) | 3.363 | 0.186   |
| Scr (μmol/L)              |             | 37.20 (18.30–67.80) | 36.50 (23.00–207.60) | 38.80 (25.30–69.70) | 0.416 | 0.812   |
| UA (mmol/L)               |             | 349.73 ± 14.53 | 357.90 ± 19.21 | 353.56 ± 27.52 | 0.055 | 0.946   |
| GFR (mL/(min⋅1.73m2))     |             | 139.62 ± 4.11 | 136.34 ± 7.52 | 135.69 ± 7.27 | 0.140 | 0.870   |
| TC (mmol/L)               |             | 9.60 ± 0.36 | 10.12 ± 0.42 | 10.42 ± 0.89 | 1.164 | 0.559   |
| TG (mmol/L)               |             | 2.60 ± 0.16 | 3.46 ± 0.30 | 2.77 ± 0.35 | 3.766 | 0.026   |
| HDL-c (mmol/L)            |             | 1.03 ± 0.06 | 1.02 ± 0.08 | 1.10 ± 0.11 | 0.218 | 0.804   |
| Fbg (g/L)                 |             | 2.25 (1.36–7.95) | 2.30 (1.36–4.79) | 1.96 (1.43–7.51) | 0.044 | 0.978   |
| HOMA-ISI                  |             | 1.24 ± 0.03 | 1.36 ± 0.05 | 1.18 ± 0.07 | 3.193 | 0.045   |
| T (CD3+) (%)              |             | 0.28 (0.10–1.13) | 0.28 (0.10–0.49) | 0.26 (0.13–0.49) | 0.412 | 0.814   |
| T (CD4+) (%)              |             | 69.85 ± 1.25 | 64.62 ± 2.44 | 72.93 ± 2.13 | 4.755 | 0.093   |
| T (CD8+) (%)              |             | 37.15 ± 1.26 | 33.77 ± 2.09 | 34.71 ± 1.50 | 1.312 | 0.275   |
| NK (%)                    |             | 10.09 ± 1.04 | 10.77 ± 1.53 | 7.57 ± 0.94 | 1.012 | 0.368   |
| FBG (mmol/L)              |             | 4.82 ± 0.08 | 4.99 ± 0.13 | 4.85 ± 0.12 | 0.733 | 0.483   |
| FISN (mU/L)               |             | 2.37 (0.20–9.43) | 1.92 (0.57–16.63) | 2.13 (0.76–12.87) | 0.180 | 0.914   |
| HOMA-IR                   |             | 37.22 (−141.54–895.56) | 38.47 (5.50–278.22) | 28.78 (13.66–224.47) | 0.192 | 0.908   |
| 24-h UP (mg/kg)           |             | 141.71 (11.25–1179.80) | 125.88 (27.69–319.00) | 176.52 (45.00–301.00) | 1.064 | 0.587   |

*$P<0.05$, **$P<0.01$.  

Table 5: The distribution of the PPAR-γ (Pro12Ala) genotypes among individuals with different renal pathological types.

| PPAR-γ genotype | IgMN n (%) | MsPGN n (%) | IgAN n (%) | FSGS n (%) | ClqN n (%) | MCD n (%) | $\chi^2$ | P value |
|-----------------|------------|-------------|------------|------------|------------|-----------|---------|---------|
| PP              | 5 (15.6%)  | 9 (28.1%)   | 3 (9.4%)   | 5 (15.6%)  | 5 (15.6%)  | 1 (3.1%)  | 5.698   | 0.285   |
| PA/AA           | 2 (6.3%)   | 0 (0%)      | 2 (6.3%)   | 0 (0%)     | 0 (0%)     | 0 (0%)    |         |         |

Table 6: The distribution of the PGC-1α (Gly482Ser) genotypes among individuals with different renal pathological types.

| PGC-1α genotype | IgMN n (%) | MsPGN n (%) | IgAN n (%) | FSGS n (%) | ClqN n (%) | MCD n (%) | $\chi^2$ | P value |
|-----------------|------------|-------------|------------|------------|------------|-----------|---------|---------|
| GG              | 2 (6.7%)   | 1 (3.3%)    | 1 (3.3%)   | 3 (10%)    | 0 (0%)     | 0 (0%)    | 11.633  | 0.252   |
| GA              | 2 (6.7%)   | 6 (20%)     | 2 (6.7%)   | 1 (3.3%)   | 4 (13.3%)  | 0 (0%)    |         |         |
| AA              | 3 (10%)    | 1 (3.3%)    | 0 (0%)     | 2 (6.7%)   | 1 (3.3%)   | 1 (3.3%)  |         |         |
Table 7: The distribution of the PPAR-γ (Pro12Ala) genotypes in groups with different responses to hormone treatment.

| PPAR-γ genotype | Hormone-sensitive group | Hormone-resistant group | Hormone-dependent group | χ² | P value |
|-----------------|-------------------------|-------------------------|-------------------------|-----|---------|
|                 | n (%)                   | n (%)                   | n (%)                   |     |         |
| PP              | 77 (71.3%)              | 13 (12.0%)              | 11 (10.2%)              | 0.779 | 0.824 |
| PA/AA           | 6 (5.6%)                | 0 (0%)                  | 1 (0.9%)                |     |         |

Table 8: The distribution of the PGC-1α (Gly482Ser) genotypes in groups with different responses to hormone treatment.

| PGC-1α genotype | Hormone-sensitive group | Hormone-resistant group | Hormone-dependent group | χ² | P value |
|-----------------|-------------------------|-------------------------|-------------------------|-----|---------|
|                 | n (%)                   | n (%)                   | n (%)                   |     |         |
| GG              | 11 (10.5%)              | 3 (2.9%)                | 3 (2.9%)                | 3.500 | 0.473 |
| GA              | 47 (44.8%)              | 6 (5.7%)                | 4 (3.8%)                |     |         |
| AA              | 24 (22.2%)              | 5 (4.8%)                | 2 (1.9%)                |     |         |

the PGC1α (Gly482Ser) gene polymorphism. We analyzed the distribution of three PGC1α genotypes in PNS and NC children and found no association between the PGC1α (Gly482Ser) genotype and PNS occurrence. However, further-stratified analysis of children with PNS showed that blood TG levels in patients with the AA genotype were significantly increased after matching for age, sex, and BMI. Previous studies have shown that PGC1α can collaborate with PPAR-α, PPAR-γ, and the farnesoid X receptor to enhance fatty acid oxidation and regulate TG metabolism [14]. Furthermore, mutations at the Gly482Ser position of the PGC1α gene could also induce functional changes in PGC1α [15]. These results suggest that functional changes in the PGC1α gene resulting from the Gly482Ser mutation may affect TG metabolism. Animal studies demonstrated that liver TG levels in PGC1α-knockout mice were increased threefold compared with the control group [16]. The results of the current study were consistent with those of previous studies, although differences in TG levels between genotypes were inconclusive.

We further analyzed glucose metabolism in PNS children and found no differences in FBG, FISN, FCP, HOMA-IR, HOMA-islet, and ISI among GG, GA, and AA genotypes. We were therefore unable to establish an association between the Gly482Ser site of the PGC1α gene and glucose metabolism disorders and IR. However, several previous studies have demonstrated a close correlation between mutations at the Gly482Ser site of PGC1α and glucose metabolism, and 482Ser was shown to increase the risk of type II diabetes in the population. Muller et al. [17] analyzed the SNPs of PGC1α in nondiabetic Pima Indians and showed that the Gly482Ser site was associated with IR. Moreover, Pima Indians with the Gly/Gly genotype had lower levels of insulin secretion following glucose loading, suggesting that the PGC1α gene could be a candidate gene for type II diabetes. This study found that patients with the Ser/Ser genotype had slightly higher FBG and HOMA-IR values and slightly lower FISN levels compared with patients with the other two genotypes, indicating that a correlation between the Gly482Ser site and glucose metabolism remains to be confirmed.

In summary, the results of this study showed no significant correlations between the PPAR-γ (Pro12Ala) and PGC1α (Gly482Ser) gene polymorphisms and the occurrence of PNS. However, mutation at the Pro12Ala position of the PPAR-γ gene may be associated with increased insulin sensitivity and decreased insulin secretion in children with PNS. Moreover, increased TG levels in patients with the PGC1α (Gly482Ser) AA genotype suggest that this polymorphism may be responsible for TG abnormalities in children with PNS.

Conflict of Interests

All the authors declared no conflict of interests, including relevant financial interests, activities, relationships, and affiliations.

Authors’ Contribution

Jiaping Jin and Guixia Ding contributed equally to this paper.

Acknowledgments

This work was supported by Grants from the National Basic Research Program of China 973 Program (nos. 2012CB517602 and 2013CB530604), the National Natural Science Foundation of China (nos. 81170635 and 81270785), the Natural Science Foundation of Jiangsu Province (no. BK2012001), and the Program for New Century Excellent Talents in University (no. NCET-12-0738).

References

[1] Y. Guan and M. D. Breyer, “Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease,” *Kidney International*, vol. 60, no. 1, pp. 14–30, 2001.
[2] H. N. Gouda, G. S. Sagoo, A.-H. Harding, J. Yates, M. S. Sandhu, and J. P. T. Higgins, “The association between the peroxisome proliferator-activated receptor-γ2 (PPARG2) Pro12Ala gene...
variant and type 2 diabetes mellitus: a HuGE review and meta-analysis," The American Journal of Epidemiology, vol. 171, no. 6, pp. 645–655, 2010.

[3] T. Sparso, M. S. Hussain, G. Andersen et al., "Relationships between the functional PPARα Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people," Molecular Genetics and Metabolism, vol. 90, no. 2, pp. 205–209, 2007.

[4] L. Andrulionytė, J. Zacharova, J.-L. Chiasson, and M. Laakso, "Common polymorphisms of the PPAR-γ2 (Pro12Ala) and PGC-1α (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial," Diabetologia, vol. 47, no. 12, pp. 2176–2184, 2004.

[5] H. Kobayashi, G. Tokudome, Y. Hara et al., "Insulin resistance is a risk factor for the progression of chronic kidney disease," Clinical Nephrology, vol. 71, no. 6, pp. 643–651, 2009.

[6] A. Jorsal, L. Tarnow, M. Laer et al., "The PPARγ2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy," Molecular Genetics and Metabolism, vol. 94, no. 3, pp. 347–351, 2008.

[7] J. Jin, B. Jin, S. Huang et al., "Insulin resistance in children with primary nephrotic syndrome and normal renal function," Pediatric Nephrology, vol. 27, pp. 1901–1909, 2012.

[8] Y. Chung-Jen, B. A. Beamer, C. Negri et al., "Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation," Biochemical and Biophysical Research Communications, vol. 241, no. 2, pp. 270–274, 1997.

[9] S. S. Deeb, L. Fajas, M. Nemoto et al., "A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity," Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998.

[10] J. Masugi, Y. Tamori, H. Mori, T. Koike, and M. Kasuga, "Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-γ 2 on thiazolidinedione-induced adipogenesis," Biochemical and Biophysical Research Communications, vol. 268, no. 1, pp. 178–182, 2000.

[11] N. Stefan, A. Fritzsche, H. Häring, and M. Stumvoll, "Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ 2 gene," Diabetes, vol. 50, no. 5, pp. 1143–1148, 2001.

[12] R. Buzzetti, A. Petrone, M. C. Ribaudo et al., "The common PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity," European Journal of Human Genetics, vol. 12, no. 12, pp. 1050–1054, 2004.

[13] J. Song, M. Sakatsume, I. Narita et al., "Peroxisome proliferator-activated receptor γ C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy," Clinical Genetics, vol. 64, no. 5, pp. 398–403, 2003.

[14] Y. Zhang, L. W. Castellani, C. J. Sinal, F. I. Gonzalez, and P. A. Edwards, "Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR," Genes and Development, vol. 18, no. 2, pp. 157–169, 2004.

[15] M.-C. Vohl, A. Houde, S. Lebel, F.-S. Hould, and P. Marceau, "Effects of the peroxisome proliferator-activated receptor-γ co-activator-1 Gly482Ser variant on features of the metabolic syndrome," Molecular Genetics and Metabolism, vol. 86, no. 1-2, pp. 300–306, 2005.

[16] S.-H. Koo, H. Satoh, S. Herzig et al., "PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3," Nature Medicine, vol. 10, no. 5, pp. 530–534, 2004.

[17] Y. L. Muller, C. Bogardus, O. Pedersen, and L. Baier, "A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor γ coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians," Diabetes, vol. 52, no. 3, pp. 895–898, 2003.